Fosinopril treatment of pregnant rats: developmental toxicity, fetal angiotensin-converting enzyme inhibition, and fetal angiotensin II receptor regulation

Grove, Kevin L.; Mayo, Rebecca; Forsyth, Carol S.; Frank, Arthur J.; Speth, Robert C.

doi:10.1016/0378-4274(95)03346-m

Cited by 5 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These deleterious effects on fetuses are thought to be due to fetal hypotension (7), as a result of inhibition of the fetal ACE. There was supportive evidence of the above in animal studies (8).…”

Section: Discussionsupporting

confidence: 60%

Exposure to angiotensin-converting enzyme inhibitors during first trimester, Is it safe to fetus?

Yip¹,

Leung²,

Fung³

1998

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 60%

Exposure to angiotensin-converting enzyme inhibitors during first trimester, Is it safe to fetus?

Yip¹,

Leung²,

Fung³

1998

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

“…The greatest reduction in blood pressure occurs within 3 to 6 h after administration (4,33), and approximates the time to peak blood levels of fosinoprilat (92). The decline in MAP is accompanied by significant reductions in systemic (23,77,82,116) and renal vascular resistance (23,82) following a single dose (Table 3) and is not associated with reflex tachycardia in either normal volunteers (27) or treated hypertensives (47,74).…”

Section: Monotherapymentioning

confidence: 99%

Fosinopril: Emerging Considerations and Implications for Angiotensin‐Converting Enzyme Inhibitor Therapy

Sica

Gehr

Kelleher

et al. 1998

Cardiovascular Drug Reviews

View full text Add to dashboard Cite

Is there an embryopathy associated with first‐trimester exposure to angiotensin‐converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence

Polifka

2012

Birth Defects Research

View full text Add to dashboard Cite

Drugs that interfere with the renin-angiotensin system, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are widely used to manage hypertension and heart failure. Adequate functioning of the RAS is essential for normal fetal kidney development. The potential for ACEIs and ARBs to impair fetal and neonatal renal function if taken after the first trimester of pregnancy has been well documented. Although these drugs were not found to be teratogenic in animals, until recently little was known about the teratogenic effects of ACEIs and ARBs in humans when exposure was limited to the first trimester of pregnancy. New evidence from epidemiologic studies indicates that there may be an elevated teratogenic risk when these drugs are taken during the first trimester of pregnancy. However, this elevated risk does not appear to be specific to ACEIs and ARBs, but is instead related to maternal factors and diseases that typically coexist with hypertension in pregnancy, such as diabetes, advanced maternal age, and obesity. Women who become pregnant while being treated with an ACEI or ARB should be advised to avoid exposure to these drugs during the second and third trimesters of pregnancy by switching to a different class of antihypertensive drugs between weeks 8 and 10 after conception.

show abstract

Fosinopril treatment of pregnant rats: developmental toxicity, fetal angiotensin-converting enzyme inhibition, and fetal angiotensin II receptor regulation

Cited by 5 publications

References 29 publications

Exposure to angiotensin-converting enzyme inhibitors during first trimester, Is it safe to fetus?

Exposure to angiotensin-converting enzyme inhibitors during first trimester, Is it safe to fetus?

Fosinopril: Emerging Considerations and Implications for Angiotensin‐Converting Enzyme Inhibitor Therapy

Is there an embryopathy associated with first‐trimester exposure to angiotensin‐converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence

Contact Info

Product

Resources

About